Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 507

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 507
---
 2023, computed in accordance with FASB Accounting Standards Codification Topic 718. For more information regarding the assumptions used in this calculation, see Note 10 to TuHURA’s financial statements included in this joint proxy 
 statement/prospectus.                                                                                                                                                                                                                  |

| (3) | Amounts in this column represent life insurance premiums paid by us on behalf of Dr. Bianco, Mr. Dearborn and                                                                        
 Mr. Yamashita. For more information regarding other compensation awarded or paid to the NEOs, see “— Narrative Disclosure to Summary Compensation Table — Other Compensation” below. |

324

| (4) | Mr. Yamashita ceased serving as an officer as of December 16, 2024. |

| (5) | Mr. Hoffman, TuHURA’s former President, Chief Executive Officer and Interim Chief Financial Officer, and                                                                                                                                        
 TuHURA were parties to a certain Executive Employment Agreement dated November 8, 2021 (the “Hoffman Employment Agreement”). On October 4, 2024, prior to the completion of the Kintara Merger, TuHURA entered into an amendment to the Hoffman 
 Employment Agreement (the “Hoffman Amendment”), pursuant to which, all outstanding stock options previously granted to Mr. Hoffman vested in full on October 4, 2024 in exchange for Mr. Hoffman agreeing to extend the non-competition         
 restrictions of the Hoffman Employment Agreement for a period of twelve months following the date that his employment terminates. Mr. Hoffman’s employment was terminated on October 18, 2024 in connection with the completion of the Kinara   
 Merger. Mr. Hoffman was appointed to the TuHURA Board of Directors in connection with the completion of the Kintara Merger.                                                                                                                     |

| (6) | The amounts included in the column above reflect (i) cumulative payment of $1,307,014 in severance payable to                                                         
 Mr. Hoffman pursuant to the Hoffman Employment Agreement and (ii) $19,002 in taxable compensation received upon the vesting and conversion of restricted stock units. |

Narrative Disclosure to Summary Compensation Table Employment Agreements Dr. James Bianco .On March 29, 2024, TuHURA entered into a second amended and restated employment agreement with Dr. Bianco under which Dr. Bianco serves as TuHURA’s President and Chief Executive Officer for an initial term of two years, unless earlier terminated. Dr. Bianco’s employment agreement provides that